Elite Trades From Anywhere

$100 Off Your First Year

00
Days
00
Hours
00
Mins
00
Sec
Claim Now
Last Close
29.89
Jul 01 • 04:00PM ET Dollar change+1.01 Percentage change(3.50%)
Index
-
Market Cap
5.55B
Enterprise Value
5.11B
Income
-250.98M
Sales
1.14B
Book/sh
5.21
Cash/sh
4.49
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
2900
IPO
Jun 05, 2020
P/E
-
Forward P/E
37.01
PEG
-
P/S
4.86
P/B
5.74
P/C
6.65
P/FCF
-
EV/EBITDA
-
EV/Sales
4.47
Quick Ratio
2.05
Current Ratio
2.13
Debt/Eq
0.40
LT Debt/Eq
0.12
Option/Short
Yes / Yes
EPS (ttm)
-1.36
EPS next Y
0.81
EPS next Q
0.07
EPS this Y
102.78%
EPS next Y
3487.99%
EPS next 5Y
-
EPS past 3/5Y
16.80% 6.49%
Sales past 3/5Y
106.67% 68.87%
EPS Y/Y TTM
-13.77%
Sales Y/Y TTM
56.70%
EPS Q/Q
46.50%
Sales Q/Q
56.66%
Insider Own
5.11%
Insider Trans
-0.16%
Inst Own
48.45%
Inst Trans
5.95%
ROA
-15.63%
ROE
-25.28%
ROIC
-23.24%
Gross Margin
51.52%
Oper. Margin
-11.57%
Profit Margin
-21.97%
SMA20
-6.36%
SMA50
3.17%
SMA200
17.17%
Trades
Shs Outstand
185.74M
Shs Float
176.25M
52W High
45.30 -34.01%
52W Low
16.24 84.05%
Volatility
5.26% 8.02%
ATR (14)
2.09
RSI (14)
49.22
Beta
0.33
Rel Volume
0.60
Avg Volume
2.75M
Volume
1,617,734
Perf Week
1.74%
Perf Month
17.17%
Perf Quarter
65.23%
Perf Half Y
36.36%
Perf YTD
37.49%
Perf Year
-17.64%
Perf 3Y
-56.70%
Perf 5Y
-28.46%
Perf 10Y
-
Prev Close
28.88
Price
29.89
Change
3.50%
Date Action Analyst Rating Change Price Target Change
Feb-12-26Downgrade Rothschild & Co Redburn Buy → Neutral $24
Jan-22-26Downgrade TD Cowen Buy → Hold $21
Jan-07-26Initiated Oppenheimer Outperform $75
Oct-07-25Initiated Cantor Fitzgerald Overweight $40
Oct-08-24Initiated Redburn Atlantic Buy $86
Jun-17-24Initiated Truist Buy $88
May-24-24Reiterated H.C. Wainwright Buy $86 → $73
May-23-24Initiated Deutsche Bank Buy $60
Apr-17-24Upgrade Scotiabank Sector Perform → Sector Outperform $65
Apr-03-24Initiated Cantor Fitzgerald Overweight $82
Jun-17-26 09:21PM
04:29PM
Jun-15-26 08:00AM
Jun-14-26 03:15AM
Jun-11-26 03:56PM
07:57AM Loading…
Jun-03-26 07:57AM
Jun-02-26 11:28AM
09:38AM
09:30AM
Jun-01-26 10:00AM
May-28-26 12:30PM
05:30AM
May-21-26 05:00PM
May-12-26 03:00PM
07:00AM
08:00AM Loading…
May-04-26 08:00AM
Apr-28-26 08:00AM
Mar-25-26 01:10PM
Mar-16-26 03:00AM
Mar-10-26 03:00PM
07:00AM
Feb-24-26 08:00AM
Feb-18-26 02:04AM
Feb-16-26 12:24PM
Feb-07-26 03:33AM
Feb-02-26 09:38AM
Jan-26-26 03:14AM
Jan-22-26 08:00AM
Jan-21-26 08:00AM
Jan-12-26 08:00AM
03:16AM Loading…
Jan-09-26 03:16AM
Dec-22-25 06:50AM
Dec-17-25 08:00AM
Dec-11-25 07:44AM
Dec-09-25 03:31PM
Dec-06-25 02:00PM
Nov-27-25 09:00AM
Nov-25-25 08:39AM
Nov-13-25 12:08PM
09:21AM
Nov-12-25 02:03PM
07:00AM
Nov-10-25 08:16PM
Nov-03-25 11:05AM
Oct-29-25 08:00AM
Oct-21-25 09:15AM
Oct-17-25 09:54PM
Oct-08-25 12:57AM
Sep-30-25 04:00AM
Aug-26-25 08:00AM
Aug-22-25 11:57PM
05:30AM
Aug-18-25 08:00AM
Aug-12-25 07:22AM
03:03AM
Aug-11-25 10:53AM
10:12AM
07:00AM
Aug-08-25 09:17AM
Jul-28-25 08:00AM
Jul-18-25 07:24AM
Jul-13-25 05:00PM
Jul-06-25 04:15AM
Jun-20-25 04:08PM
Jun-03-25 10:45AM
May-22-25 05:15PM
May-19-25 08:00AM
May-14-25 09:18AM
03:06AM
12:24AM
May-13-25 07:00AM
May-12-25 09:20AM
May-03-25 04:51AM
May-02-25 12:00PM
09:55AM
Apr-29-25 08:00AM
Apr-24-25 06:53AM
Apr-16-25 09:53AM
Apr-11-25 12:30AM
Apr-09-25 05:53AM
Apr-01-25 11:50AM
Mar-12-25 03:02AM
01:34AM
Mar-11-25 09:30AM
07:00AM
Feb-25-25 08:00AM
Feb-23-25 01:29PM
Feb-21-25 09:43AM
Feb-20-25 12:18PM
Feb-13-25 02:06PM
Feb-08-25 09:29AM
Jan-30-25 05:01PM
Jan-17-25 11:04AM
Dec-19-24 08:01AM
Dec-11-24 07:22AM
Dec-09-24 07:35PM
04:22PM
Nov-27-24 10:02AM
Nov-22-24 07:31AM
Nov-21-24 05:28PM
Legend Biotech Corp. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, manufacturing, and commercialization of novel therapies for oncology and other indications. The firm develops advanced cell therapies across a diverse array of technology platforms, including autologous and allogeneic chimeric antigen receptor T-cell, gamma-delta T cell and natural killer cell-based immunotherapy. It operates through the following geographical segments: United States of America, China, and Other. The company was founded in 2014 and is headquartered in Somerset, NJ.
CEO & DirectorDr. Ying Huang Ph.D.
Chief Financial OfficerMr. Carlos Santos
Vice President of FinanceMs. Jessie Yeung M.B.A.
General CounselMr. James Pepin J.D.
J.D.Ms. Ananda Elizabeth Martin Esq.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Casey Patrick JohnDirectorJun 30 '26Proposed Sale29.603,00088,800Jun 30 10:46 AM
Huang YingChief Executive OfficerJun 25 '26Sale14.785,56682,265241,872Jun 29 09:53 PM
Huang YingOfficerJun 26 '26Proposed Sale28.392,78379,017Jun 26 03:23 PM
Huang YingChief Executive OfficerMar 25 '26Sale8.779,93687,139247,438Mar 27 04:25 PM
Huang YingOfficerMar 26 '26Proposed Sale17.544,96887,149Mar 26 04:27 PM
Yeung JessieOfficerMar 26 '26Proposed Sale17.541,86232,663Mar 26 04:20 PM
Huang YingOfficerDec 26 '25Proposed Sale22.5264,3391,449,074Dec 29 07:28 AM
Sanders Corazon (Corsee) D.DirectorDec 24 '25Proposed Sale22.7796922,064Dec 29 06:45 AM
Huang YingOfficerDec 24 '25Proposed Sale22.9561,4671,410,606Dec 29 06:40 AM
GenScript CorporationAffiliateNov 17 '25Proposed Sale30.29203,5866,166,620Nov 17 05:50 PM
Casey Patrick JohnDirectorSep 26 '25Proposed Sale33.281,00033,285Sep 26 04:24 PM
Huang YingOfficerSep 24 '25Proposed Sale33.001,37045,210Sep 24 10:02 AM
Huang YingOfficerSep 23 '25Proposed Sale33.981,35746,112Sep 23 03:13 PM
Yeung JessieOfficerSep 23 '25Proposed Sale33.9847416,107Sep 23 03:13 PM
Sanders Corazon (Corsee) D.DirectorSep 23 '25Proposed Sale34.0030710,438Sep 23 09:47 AM
Huang YingOfficerJul 23 '25Proposed Sale45.0415,291688,723Jul 23 04:11 PM
Yeung JessieOfficerJul 23 '25Proposed Sale45.0064228,890Jul 23 12:00 PM